Zagotenemab在早期症状性阿尔茨海默病中的疗效与安全性评估:PERISCOPE-ALZ 2期研究结果
PERISCOPE-ALZ是一项在北美和日本56个中心开展的双盲2期研究,将360例早期症状性阿尔茨海默病患者随机分配至zagotenemab 1,400 mg、5,600 mg或安慰剂组,每4周静脉输注一次,持续100周。主要终点iADRS的疾病进展比值在低剂量组为1.10(95%可信区间0.959-1.265),高剂量组为1.05(0.907-1.209),均未显示显著延缓临床进展。影像学生物标志物和血浆NfL未显示药效学活性或疾病修饰证据。
要点
- zagotenemab未能显著延缓早期症状性AD的临床疾病进展。
- 低剂量组iADRS疾病进展比值为1.10(95%可信区间0.959-1.265),高剂量组为1.05(0.907-1.209)。
- 治疗组不良事件发生率85.1%,高于安慰剂组的74.6%,但差异无特定不良事件归因。
核心结论
- 在早期症状性AD参与者中,与安慰剂相比,zagotenemab未能实现临床疾病进展的显著延缓。
- 影像学生物标志物和血浆NfL发现未显示药效学活性或疾病修饰的证据。
研究设计与样本
- PERISCOPE-ALZ是一项在北美和日本56个中心开展的双盲2期研究。
- 共360例参与者随机分配至zagotenemab 1,400 mg、5,600 mg或安慰剂组,每4周静脉输注一次,持续100周。
- 关键入选标准包括年龄60-85岁、简易精神状态检查评分20-28分、PET成像显示中等水平脑tau。
- 主要终点为采用贝叶斯疾病进展模型评估的整合AD评定量表(iADRS)变化。
主要发现
- iADRS的疾病进展比值(治疗组相对安慰剂组的比例下降)在zagotenemab低剂量组为1.10(95%可信区间0.959-1.265),高剂量组为1.05(0.907-1.209),比值小于1有利于治疗组。
- 次要临床终点指标未能显示zagotenemab相对于安慰剂的药物-安慰剂差异。
- flortaucipir PET、容积MRI或神经丝轻链(NfL)分析均未显示治疗效果。
- 血浆磷酸化tau181和总tau出现剂量相关的升高。
- zagotenemab治疗组报告的不良事件发生率(85.1%)高于安慰剂组(74.6%),该差异不能归因于任何特定不良事件或不良事件类别。
关键数值与推荐
- iADRS疾病进展比值低剂量组为1.10(95%可信区间0.959-1.265),高剂量组为1.05(0.907-1.209),比值小于1有利于治疗组。
- 治疗组不良事件发生率为85.1%,安慰剂组为74.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Zagotenemab (LY3303560), a monoclonal antibody that preferentially targets misfolded, extracellular, aggregated tau, was assessed in the PERISCOPE-ALZ phase 2 study to determine its ability to slow cognitive and functional decline relative to placebo in early symptomatic Alzheimer disease (AD). METHODS: Participants were enrolled across 56 sites in North America and Japan. Key eligibility criteria included age of 60-85 years, Mini-Mental State Examination score of 20-28, and intermediate levels of brain tau on PET imaging. In this double-blind study, participants were equally randomized to 1,400 mg or 5,600 mg of zagotenemab, or placebo (IV infusion every 4 weeks for 100 weeks). The primary outcome was change on the Integrated AD Rating Scale (iADRS) assessed by a Bayesian Disease Progression model. Secondary measures include mixed model repeated measures analysis of additional cognitive and functional endpoints as well as biomarkers of AD pathology. RESULTS: A total of 360 participants (mean age = 75.4 years; female = 52.8%) were randomized, and 218 completed the treatment period. Demographics and baseline characteristics were reasonably balanced among arms. The mean disease progression ratio (proportional decline in the treated vs placebo group) with 95% credible intervals for the iADRS was 1.10 (0.959-1.265) for the zagotenemab low-dose group and 1.05 (0.907-1.209) for the high-dose, where a ratio less than 1 favors the treatment group. Secondary clinical endpoint measures failed to show a drug-placebo difference in favor of zagotenemab. No treatment effect was demonstrated by flortaucipir PET, volumetric MRI, or neurofilament light chain (NfL) analyses. A dose-related increase in plasma phosphorylated tau181 and total tau was demonstrated. Zagotenemab treatment groups reported a higher incidence of adverse events (AEs) (85.1%) compared with the placebo group (74.6%). This difference was not attributable to any specific AE or category of AEs. DISCUSSION: In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression compared with placebo. Imaging biomarker and plasma NfL findings did not show evidence of pharmacodynamic activity or disease modification. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT03518073. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with early symptomatic AD, zagotenemab does not slow clinical disease progression.
引用
- Fleisher AS, Munsie LM, Perahia DGS, et al. Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. Neurology. 2024. PMID: 38386949. doi:10.1212/WNL.0000000000208061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。